Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

ClinicalTrials.gov ID: NCT07711002

Public ClinicalTrials.gov record NCT07711002. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, 2-Cohort, Phase III Study of Saruparib Combined With Physician's Choice of Androgen Receptor Pathway Inhibitor in Patients With Metastatic Hormone-Sensitive Prostate Cancer, Previously Treated With Docetaxel or PSMA-directed 177Lutetium-Containing Therapy Without Disease Progression, and With Prostate-Specific Antigen ≥ 0.2 ng/mL: EvoPAR-Prostate05

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received docetaxel chemotherapy or a prostate-specific membrane antigen (PSMA)-directed lutetium-177 radioligand therapy with no evidence of disease progression and PSA ≥ 0.2 ng/mL.

Study identification

NCT ID: NCT07711002
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 1,330 participants

Conditions and interventions

Conditions

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 15, 2026 (Actual)
Primary completion: May 30, 2031 (Estimated)
Completion: May 27, 2033 (Estimated)
Last update posted: Oct 15, 2026

2026 – 2033

United States locations

U.S. sites: 42
U.S. states: 20
U.S. cities: 39

Facility	City	State	ZIP	Site status
Research Site	Hot Springs	Arkansas	71913	Not yet recruiting
Research Site	Springdale	Arkansas	72762	Recruiting
Research Site	Beverly Hills	California	90211	Not yet recruiting
Research Site	Los Alamitos	California	90720	Not yet recruiting
Research Site	Los Angeles	California	90089	Not yet recruiting
Research Site	San Diego	California	92123	Withdrawn
Research Site	Margate	Florida	33063	Recruiting
Research Site	Miami	Florida	33165	Recruiting
Research Site	Orlando	Florida	32806	Not yet recruiting
Research Site	Honolulu	Hawaii	96813	Not yet recruiting
Research Site	Chicago	Illinois	60637	Not yet recruiting
Research Site	Chicago	Illinois	60657	Not yet recruiting
Research Site	Elk Grove Village	Illinois	60007	Not yet recruiting
Research Site	Hinsdale	Illinois	60521	Not yet recruiting
Research Site	Ames	Iowa	50010	Not yet recruiting
Research Site	Baltimore	Maryland	21201	Not yet recruiting
Research Site	Baltimore	Maryland	21229	Not yet recruiting
Research Site	Towson	Maryland	21204	Not yet recruiting
Research Site	Detroit	Michigan	48202	Not yet recruiting
Research Site	Grand Rapids	Michigan	49503	Not yet recruiting
Research Site	Marshall	Minnesota	56258	Not yet recruiting
Research Site	Camden	New Jersey	08103	Not yet recruiting
Research Site	Albuquerque	New Mexico	87109	Not yet recruiting
Research Site	Shirley	New York	11967	Not yet recruiting
Research Site	Canton	Ohio	44718	Not yet recruiting
Research Site	Cincinnati	Ohio	45267	Not yet recruiting
Research Site	Portland	Oregon	97213	Not yet recruiting
Research Site	Portland	Oregon	97227	Not yet recruiting
Research Site	Greenville	South Carolina	29607	Not yet recruiting
Research Site	Aberdeen	South Dakota	57401	Not yet recruiting
Research Site	Mitchell	South Dakota	57301	Not yet recruiting
Research Site	Pierre	South Dakota	57501	Not yet recruiting
Research Site	Sioux Falls	South Dakota	57105	Not yet recruiting
Research Site	Yankton	South Dakota	57078	Not yet recruiting
Research Site	Nashville	Tennessee	37203	Not yet recruiting
Research Site	Austin	Texas	78745	Not yet recruiting
Research Site	Dallas	Texas	75235	Not yet recruiting
Research Site	Fort Worth	Texas	76104	Not yet recruiting
Research Site	Longview	Texas	75605	Not yet recruiting
Research Site	Wichita Falls	Texas	76310	Not yet recruiting
Research Site	Salt Lake City	Utah	84112	Withdrawn
Research Site	Spokane	Washington	99202	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 168 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07711002, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 15, 2026 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07711002 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →